Objective: To evaluate the clinical efficacy and safety of intravenous sparfloxacin lactate (SPLX) administration in the treatment of bacterial infections. Methods: A randomized open trial was conducted in 3 multicenter controlled trials. 160 patients were admitted into the study

including 60 cases in the control group (ofloxacin

OFLX).The dosage of SPLX was 200mg qd and that of OFLX was 200mg bid. Results-. In the SPLX group

88.3% of patients were clinically cured or improved compared with 81.7% of the patients in the OFLX group (P>0.05).The eradication rates of pathogens were 91.1% and 90%

respectively (P>0.05). Bacterial eradication rates were similar in both treatment groups. Drug -related adverse events were reported in 12% of patients receiving SPLX and in 10% of patients administered of OFLX. Gastrointestinal and rash adverse events were the most common ones reported in each treatment group. There is no photosensitivity reaction in both groups. The results of in vitro activity of SPLX showed good activity against many Gram - negative organ- isms and were similar to those of OFLX. The activity against Gram- positive organisms was higher than that of OFLX. Conclusion : Intravenous treatment with 200mg SPLX qd is as effective as the treatment with 200mg OFLX bid in patients with acute and serious infectious diseases caused by sensitive pathogens.